Standalone and Consolidated Audited Financial result for the Fourth quarter and Year ended on March 31, 2026.
KOPRAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kopran Ltd reported consolidated revenue of ₹68,142.36 lakh for FY26, up 8.2% from ₹62,960.44 lakh in FY25, driven by higher pharmaceutical sales. However, profit after tax declined sharply to ₹2,573.12 lakh from ₹3,855.19 lakh in FY25 — a 33.3% drop — reflecting margin compression likely due to increased material costs, higher finance costs (₹1,047 lakh vs ₹934 lakh), and foreign exchange losses. The standalone PAT improved to ₹3,039.97 lakh from ₹2,685.62 lakh, indicating the group's profit decline was driven by subsidiary performance. Auditors (Khandelwal Jain & Co.) issued an Unmodified Opinion with no qualifications. The Board recommended a dividend of ₹3 per share (30%). The company also announced a proposed merger of Kopran Laboratories Limited into Kopran Limited, pending NCLT approval.
Revenue grew modestly but bottom-line fell sharply due to higher input costs and finance charges, raising concerns about margin sustainability. The proposed merger could strengthen consolidated financials going forward.